Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective
N Drosu, G Giovannoni, D Pohl… - Multiple Sclerosis …, 2021 - msard-journal.com
2 mononuclear cells (Hoover et al., 2008), which is consistent with the sharp reduction in
relapses and MRI activity observed in trials for MS (Hauser et al., 2017). If anti-CD20
therapies are acting as nonspecific antiviral agents, it may be possible to target EBV directly
and avoid side effects due to systemic immunosuppression. Early trials using adoptive
transfer of autologous EBV-specific cytotoxic T-cells to treat advanced progressive MS have
reported promising preliminary results that support targeting EBV (Pender et al., 2018) …
relapses and MRI activity observed in trials for MS (Hauser et al., 2017). If anti-CD20
therapies are acting as nonspecific antiviral agents, it may be possible to target EBV directly
and avoid side effects due to systemic immunosuppression. Early trials using adoptive
transfer of autologous EBV-specific cytotoxic T-cells to treat advanced progressive MS have
reported promising preliminary results that support targeting EBV (Pender et al., 2018) …